The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer
Authors:
- 1 October 2007
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 4 (10) , 542-549
Abstract
Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in per-patient terms. Significant costs are attributable to the treatment of recurrences and complications. Fluorescence-guided cystoscopy, using 5-aminolevulinic acid (ALA) or its hexyl ester, hexaminolevulinate 5-ALA (Hexvix® [HAL], Photocure, Oslo, Norway), improves the detection of bladder tumors, particularly carcinoma in situ, compared with standard white-light cystoscopy. The quality of transurethral resection of the bladder tumor is also improved. It has been shown that improved tumor detection leads to better patient management and, in the case of ALA, reduced long-term recurrence rates and costs. Long-term studies in this area with HAL are ongoing. The technique is well tolerated and is a useful adjunct to white-light cystoscopy.Keywords
This publication has 47 references indexed in Scilit:
- Clinical model of lifetime cost of treating bladder cancer and associated complicationsUrology, 2006
- Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladderBJU International, 2006
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- LONG-TERM BENEFIT OF 5-AMINOLEVULINIC ACID FLUORESCENCE ASSISTED TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER: 5-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDYJournal of Urology, 2005
- Bladder cancer: Epidemiology, staging and grading, and diagnosisUrology, 2005
- 5‐aminolaevulinic acid‐induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancerBJU International, 2005
- A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?European Urology, 2004
- The health economics of bladder cancerPharmacoEconomics, 2003
- Variability in the Recurrence Rate at First Follow-up Cystoscopy after TUR in Stage Ta T1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC StudiesEuropean Urology, 2002
- Guidelines on Bladder CancerEuropean Urology, 2002